C4U and Noile-Immune Biotech partnership on PRIME allogeneic CAR-T cell therapy

Noile-Immune Biotech Inc., (“Noile-Immune”) and C4U Corporation, (“C4U”) announced that they have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U’s CRISPR/Cas3 genome editing technology and Noile-Immune’s PRIME (Proliferation inducing and migration enhancing) technology designed to improve proliferation and trafficking of immune cells into solid tumors.…

Study finds strong evidence for a causal link between long-term exposure to fine air particles and greater mortality in elderly Americans

A new analysis of 16 years of publicly accessible health data on 68.5 million Medicare enrollees provides broad evidence that long-term exposure to fine particles in the air – even at levels below current EPA standards – leads to increased mortality rates among the elderly. Based on the results of five complementary statistical models, including…